Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetically Modified T Cells in Malignant Tumors
NCT06515626Phase 1Recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ISIKOK-19 in non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC), gastric cancer (GC) and 10 more. Primary endpoint: Progression-Free Survival at 36 months. Started Aug 2024; status: recruiting.
02
Drugs
ISIKOK-19
03
Conditions
non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)gastric cancer (GC)colorectal cancer (CRC)liver cancer
Beyond the preview
Go deeper on NCT06515626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06515626.